Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Allurion Technologies ( (ALUR) ).
Allurion Technologies announced an Omnibus Amendment to its existing financial agreements, which includes maintaining certain cash balances and revenue requirements. It also entails securing marketing authorizations in France and the U.S. for its products. The amendment allows investors to receive common stock or preferred shares, and it grants the right for investor representatives to join the board of directors, indicating a strategic move to strengthen financial and operational stability.
More about Allurion Technologies
Allurion Technologies, Inc. operates in the healthcare industry and focuses on developing and commercializing medical devices. The company’s primary products include the Allurion Balloon, a weight loss device, and it also offers a Virtual Care Suite platform and a compounded GLP-1 program. Allurion aims to expand its market presence in the United States and internationally.
YTD Price Performance: -27.26%
Average Trading Volume: 24,077
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $24.05M
For an in-depth examination of ALUR stock, go to TipRanks’ Stock Analysis page.